Zebrafish Xenografts for Drug Discovery and Personalized Medicine
| Autor: | Eric Glasgow, Jerry Xiao, Seema Agarwal |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Cancer Research Embryo Nonmammalian Time Factors Xenotransplantation medicine.medical_treatment Cell Culture Techniques Antineoplastic Agents Disease Article Animals Genetically Modified Mice 03 medical and health sciences 0302 clinical medicine Cell Line Tumor Neoplasms Drug Discovery medicine Animals Humans Epigenetics Precision Medicine Zebrafish Transplantation Chimera biology business.industry Drug discovery Cancer medicine.disease biology.organism_classification Xenograft Model Antitumor Assays High-Throughput Screening Assays 030104 developmental biology Oncology 030220 oncology & carcinogenesis Cancer research Personalized medicine business Ex vivo |
| Zdroj: | Trends Cancer |
| ISSN: | 2405-8033 |
| DOI: | 10.1016/j.trecan.2020.03.012 |
| Popis: | Cancer is the second leading cause of death in the world. Given that cancer is a highly individualized disease, predicting the best chemotherapeutic treatment for individual patients can be difficult. Ex vivo models such as mouse patient-derived xenografts (PDX) and organoids are being developed to predict patient-specific chemosensitivity profiles before treatment in the clinic. Although promising, these models have significant disadvantages including long growth times that introduce genetic and epigenetic changes to the tumor. The zebrafish xenograft assay is ideal for personalized medicine. Imaging of the small, transparent fry is unparalleled among vertebrate organisms. In addition, the speed (5–7 days) and small patient tissue requirements (100–200 cells per animal) are unique features of the zebrafish xenograft model that enable patient-specific chemosensitivity analyses. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|